skip to main content

Hypertensive acute cardiogenic pulmonary oedema with acidaemia — MRCEM SBA MCQ

Instant feedback + full explanation. One question, done properly.

HardCardiovascular emergenciesHypertensive acute cardiogenic pulmonary oedema with acidaemiaMRCEM SBA

A 71-year-old woman with known left ventricular systolic dysfunction presents with rapidly worsening breathlessness. She is sitting upright, alert and able to cooperate with treatment, but can speak only in single words. Her blood pressure is 218/116 mmHg, pulse 118/min and oxygen saturation 88% despite high-concentration oxygen. She has widespread bilateral crackles and diffuse B-lines on lung ultrasound. Arterial blood gas analysis shows pH 7.26 and PaCO₂ 6.8 kPa. The ECG shows sinus tachycardia without acute ischaemic changes. Monitoring and intravenous access are established. Which initial treatment and disposition plan is most appropriate?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: E — Start non-invasive ventilation, give intravenous furosemide and glyceryl trinitrate, and arrange level 2 care.

This is acute cardiogenic pulmonary oedema with severe dyspnoea, hypoxaemia and acidaemia. Although non-invasive ventilation is not recommended routinely for pulmonary oedema, these features meet NICE’s exception for considering it without delay. Intravenous diuretic therapy is indicated. The marked hypertension also makes intravenous glyceryl trinitrate a reasonable additional treatment, provided blood pressure is closely monitored where at least level 2 care can be delivered. ([nice.org.uk](https://www.nice.org.uk/guidance/cg187/chapter/recommendations)) A is tempting because oxygenation is poor, but she remains alert and cooperative; immediate intubation is not the best first step before a trial of indicated non-invasive ventilation. B gives appropriate drugs but delays ventilatory support despite severe dyspnoea and acidaemia. C offers the right ventilatory support and diuretic but substitutes dobutamine, an inotrope considered for potentially reversible cardiogenic shock, for which her profound hypertension provides no indication. D selects the appropriate initial treatments but places intravenous nitrate treatment and non-invasive ventilation on a general ward rather than in a setting capable of the required close monitoring. E integrates respiratory support, pharmacological treatment and disposition. ([nice.org.uk](https://www.nice.org.uk/guidance/cg187/chapter/recommendations))

Reference: NICE CG187: Acute heart failure: diagnosis and management — recommendations 1.4.1–1.4.3 (17 November 2021) — https://www.nice.org.uk/guidance/cg187/chapter/recommendations NICE CG187: Acute heart failure: diagnosis and management — recommendations 1.3.3 and 1.3.7–1.3.8 (17 November 2021) — https://www.nice.org.uk/guidance/cg187/chapter/recommendations NICE CG187: Acute heart failure: diagnosis and management — recommendations 1.3.10–1.3.11 (17 November 2021) — https://www.nice.org.uk/guidance/cg187/chapter/recommendations